Research

Publicacions científiques

  • Muñoz-Mármol AM, Meléndez B, Hernandez A, Sanz C, Domenech M, Arpí-Llucia O, Gut M, Esteve A, Esteve-Codina A, Parra G, Carrato C, Aldecoa I, Mallo M, Pineda E, Alameda F, de la Iglesia N, Martinez-Balibrea E, Martinez-Cardús A, Estival-Gonzalez A and Balana C.

    Multikinase Treatment of Glioblastoma: Evaluating the Rationale for Regorafenib.

    Cancers 17(3):

    [doi:10.3390/cancers17030375]

  • Teruel, I, Castellà, E, Recalde, S, Viñas, G, Petit, A, Trigueros, M, Martínez-Balibrea, E, Felip, E, Bergamino, M, Bernat-Peguera, A, Cirauqui, B, Quiroga, V, Ferrando-Díez, A, Pous, A, López, A, Boronat, L, Soler, G, Recuero, J, Romeo, M, Guillén, P, Mesía, R, Ballana, E, Martínez-Cardús, A and Margelí, M.

    Assessing the Prognostic Value of Cytoplasmic and Stromal Caveolin-1 in Early Triple-Negative Breast Cancer Undergoing Neoadjuvant Chemotherapy

    International Journal of Molecular Sciences 25(22):

    [doi:10.3390/ijms252212241]

  • Cabrero-de las Heras, S, Hernández-Yagüe, X, González, A, Losa, F, Soler, G, Bugés, C, Baraibar, I, Esteve, A, Pardo-Cea, MA, Ree, AH, Martínez-Bosch, N, Nieva, M, Musulén, E, Meltzer, S, Lobato, T, Vendrell-Ayats, C, Queralt, C, Navarro, P, Montagut, C, Grau-Leal, F, Camacho, D, Legido, R, Mulet-Margalef, N and Martínez-Balibrea, E.

    Changes In Serum CXCL13 Levels Are Associated With Outcomes of Colorectal Cancer Patients Undergoing First-Line Oxaliplatin-Based Treatment

    BIOMEDICINE & PHARMACOTHERAPY 176:

    [doi:10.1016/j.biopha.2024.116857]

  • Lopez-Bujanda ZA, Hadavi SH, Ruiz De Porras V, Martínez-Balibrea E and Dallos MC.

    Chemotactic signaling pathways in prostate cancer: Implications in the tumor microenvironment and as potential therapeutic targets.

    International Review of Cell and Molecular Biology 388: 162-205

    [doi:10.1016/bs.ircmb.2024.03.008]

  • Moreta-Moraleda, Cristina, Queralt, Cristina, Vendrell-Ayats, Carla, Forcales, Sonia and Martinez-Balibrea, Eva.

    Chromatin factors: Ready to roll as biomarkers in metastatic colorectal cancer?

    Pharmacological Research 196:

    [doi:10.1016/j.phrs.2023.106924]

  • Layos, L, Martinez-Balibrea, E and de Porras, VR.

    Curcumin: A Novel Way to Improve Quality of Life for Colorectal Cancer Patients?

    International Journal of Molecular Sciences 23(22):

    [doi:10.3390/ijms232214058]

  • Bernat-Peguera, A, Trigueros, M, Ferrando-Diez, A, Ibanez, C, Bystrup, S, Martinez-Cardus, A, Margeli, M and Martinez-Balibrea, E.

    Efficacy of CT-P6 (trastuzumab biosimilar) versus reference trastuzumab in combination with pertuzumab in HER2-positive early-stage breast cancer: Preclinical and real-life clinical data

    Breast 62: 1-9

    [doi:10.1016/j.breast.2022.01.007]

  • Domenech, M, Hernandez, A, Plaja, A, Martinez-Balibrea, E and Balana, C.

    Hypoxia: The Cornerstone of Glioblastoma

    International Journal of Molecular Sciences 22(22):

    [doi:10.3390/ijms222212608]

  • Ruiz de Porras V, Layos L and Martínez-Balibrea E.

    Curcumin: A therapeutic strategy for colorectal cancer?

    Seminars in Cancer Biology 73: 321-330

    [doi:10.1016/j.semcancer.2020.09.004]

  • de Porras, VR, Wang, XC, Palomero, L, Marin-Aguilera, M, Sole-Blanch, C, Indacochea, A, Jimenez, N, Bystrup, S, Bakht, M, Conteduca, V, Piulats, JM, Buisan, O, Suarez, JF, Pardo, JC, Castro, E, Olmos, D, Beltran, H, Mellado, B, Martinez-Balibrea, E, Font, A and Aytes, A.

    Taxane-induced Attenuation of the CXCR2/BCL-2 Axis Sensitizes Prostate Cancer to Platinum-based Treatment

    European Urology 79(6): 722-733

    [doi:10.1016/j.eururo.2020.10.001]

  • de Porras, VR, Bystrup, S, Cabrero-de las Heras, S, Musulen, E, Palomero, L, Alonso, MH, Nieto, R, Arango, D, Moreno, V, Queralt, C, Manzano, JL, Layos, L, Buges, C and Martinez-Balibrea, E.

    Tumor Expression of Cyclin-Dependent Kinase 5 (Cdk5) Is a Prognostic Biomarker and Predicts Outcome of Oxaliplatin-Treated Metastatic Colorectal Cancer Patients

    Cancers 11(10):

    [doi:10.3390/cancers11101540]

  • Morán T, Felip E, Bosch-Barrera J, de Aguirre I, Ramirez JL, Mesia C, Carcereny E, Roa D, Sais E, García Y, Blanco R, Sanchez S, Villacorta CR, Queralt C, Velarde JM and Rosell R.

    Correction: Monitoring EGFR-T790M mutation in serum/plasma for prediction of response to third-generation EGFR inhibitors in patients with lung cancer.

    Oncotarget 10(26): 2576-2576

    [doi:10.18632/oncotarget.26855]